GLP-1 Drugs May Modestly Raise Optic Neuropathy Risk in T2D

by Medscape • 2026/05/04 • 0 Comments

GLP-1 therapy is linked to a modestly increased risk for nonarteritic anterior ischemic optic neuropathy compared with SGLT2 inhibitors in veterans with type 2 diabetes.
Medscape Medical News

← OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use →

Post navigation